Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus. The mature form of Complement C5 is a disulfide-linked heterodimer composed of proteolytically cleaved α and β chain. During cultivation, Complement C5 will be partially processed into α and β chain and has a calculated MW of 73.8 kDa (β chain) and 111.9 kDa (α chain) respectively. The protein migrates as 80 kDa (β chain), 120 kDa (α chain) and 200 kDa (α & β chain) under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Rabbit Complement C5, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Eculizumab | 5G1-1; HAL-1; LEX-98; h-5G1.1 | Approved | Alexion Pharmaceuticals Inc | Soliris | Mainland China | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Alexion Europe Sas | 2007-03-16 | Neuromyelitis Optica; Macular Degeneration; Diabetes Mellitus; Kidney Failure, Chronic; Thrombocytopenia; Guillain-Barre Syndrome; Urea Cycle Disorders, Inborn; Asthma; Nasopharyngeal Carcinoma; Glomerulonephritis, Membranoproliferative; Pre-Eclampsia; Anemia, Hemolytic, Autoimmune; Myasthenia Gravis; Infant, Newborn, Diseases; Antiphospholipid Syndrome; Delayed Graft Function; Atypical Hemolytic Uremic Syndrome; Rejection of organ transplantation; Vagus Nerve Diseases; Hemoglobinuria, Paroxysmal; End Stage Liver Disease; Rejection of renal transplantation; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; HELLP Syndrome | Details |
Ravulizumab | ALXN-1810; ALXN-1210 | Approved | Alexion Pharmaceuticals Inc, Xencor Inc | Ultomiris | EU | Myasthenia Gravis | Alexion Europe Sas | 2018-12-21 | Myasthenia Gravis; Dermatomyositis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Thrombotic Microangiopathies; Lupus Nephritis; Atypical Hemolytic Uremic Syndrome; Acute Kidney Injury; Neuromyelitis Optica; Pneumonia, Viral; Amyotrophic Lateral Sclerosis; Acute Lung Injury | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
ALXN-5500 | ALXN-5500 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
Eculizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Hemoglobinuria, Paroxysmal | Details | |
Eculizumab biosimilar (IBC GENERIUM) | Phase 3 Clinical | Ibc Generium | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details | |
Vilobelimab | CaCP-29; IFX-1 | Phase 3 Clinical | Inflarx Nv | Shock, Septic; Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Drug-Related Side Effects and Adverse Reactions; Microscopic Polyangiitis; Pyoderma Gangrenosum; Sepsis; Coronavirus Disease 2019 (COVID-19); Lung Diseases, Interstitial; Hidradenitis Suppurativa; Systemic Inflammatory Response Syndrome | Details |
Eculizumab biosimilar (Amgen) | ABP-959 | Phase 3 Clinical | Amgen Inc | Hemoglobinuria, Paroxysmal | Details |
IM-101 | IM-101 | Phase 1 Clinical | ImmunAbs Inc | Autoimmune Diseases | Details |
Zilucoplan | RA-101495-SC; RA-101495 | Phase 3 Clinical | Ucb Sa, Ra Pharma | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Muscular Diseases | Details |
Nomacopan | EV-576; rVA576; rEV-576 | Phase 3 Clinical | Evolutec | Hemoglobinuria, Paroxysmal; Thrombotic Microangiopathies; Pemphigoid, Bullous; Keratoconjunctivitis | Details |
STSA-1002 | STSA1002; STSA-1002 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
Eculizumab biosimilar (Biocad) | BCD-148 | Phase 3 Clinical | Biocad | Hemoglobinuria, Paroxysmal | Details |
Avacincaptad pegol | ARC-187; ARC-1905 | Phase 3 Clinical | Archemix Corp | Geographic Atrophy; Stargardt Disease; Macular Degeneration | Details |
Gefurulimab | TPP-2511; ALXN-1720; CON-9978 | Phase 3 Clinical | Alexion Pharmaceuticals Inc | Myasthenia Gravis; Proteinuria | Details |
P-014 | P014; KP-104 | Phase 2 Clinical | Kira Pharmaceuticals LLC | Hemoglobinuria, Paroxysmal; Lupus Erythematosus, Systemic; Glomerulonephritis | Details |
Pozelimab | REGN-3918 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies | Details |
Cemdisiran | ALN-62643; ALN-CC5; AD-62643 | Phase 3 Clinical | Alnylam Pharmaceuticals Inc | Myasthenia Gravis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
eculizumab biosimilar(Isu Abxis) | ISU-305 | Phase 1 Clinical | Isu Abxis Co Ltd | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
Eculizumab biosimilar (Samsung Bioepis) | SB-12 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Hemoglobinuria, Paroxysmal | Details |
CAN-106 | CAN-106 | Phase 2 Clinical | Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd | Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn | Details |
BDB-001 | BDB-001; BDB001; BDB 001; BDB-1 | Phase 3 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Solid tumours; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa | Details |
This web search service is supported by Google Inc.